Short Interest in Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Drops By 91.3%

Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) was the target of a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 140 shares, a decline of 91.3% from the July 30th total of 1,608 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 1,984 shares, the days-to-cover ratio is presently 0.1 days.

Mosaic ImmunoEngineering Price Performance

Shares of OTCMKTS:CPMV remained flat at $0.06 on Tuesday. 11 shares of the stock traded hands, compared to its average volume of 1,073. The stock’s 50-day moving average is $0.49 and its 200-day moving average is $0.57. Mosaic ImmunoEngineering has a 12-month low of $0.05 and a 12-month high of $1.05. The company has a market cap of $441,640.00, a price-to-earnings ratio of -0.68 and a beta of -0.82.

Mosaic ImmunoEngineering (OTCMKTS:CPMV) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.